<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04516655</url>
  </required_header>
  <id_info>
    <org_study_id>C-R-HDMTX</org_study_id>
    <nct_id>NCT04516655</nct_id>
  </id_info>
  <brief_title>A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients</brief_title>
  <acronym>C-R-HDMTX</acronym>
  <official_title>A Phase II， Single-arm Trail of Chidamide Combined With Rituximab and High-dose Methotrexate in Previously Untreated Patients With Primary Central Nervous System Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy, safety and patient reported outcomes of chidamide 20&#xD;
      mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given&#xD;
      on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central&#xD;
      nervous system lymphoma.&#xD;
&#xD;
      The primary study endpoint will be complete response (CR) rate as assessed by the&#xD;
      investigator. The hypothesis is previously untreated patients with primary central nervous&#xD;
      system lymphoma could achieve a CR rate of 80% with C-R-HDMTX.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CR rate</measure>
    <time_frame>up to 18 weeks</time_frame>
    <description>CR rate of the lesion of previously untreated patients with primary central nervous system lymphoma according to the international collaborative evaluation criteria for central nervous system lymphoma （2005）with Enhanced MRI every 2 cycles</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">51</enrollment>
  <condition>Central Nervous System Lymphoma</condition>
  <arm_group>
    <arm_group_label>C-R-MTX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>chidamide combined with rituximab and high-dose methotrexate</intervention_name>
    <description>chidamide 20 mg biw PO day1-14 and rituximab 375 mg/m2 IV given on day 1 and methotrexate 3.5g/m2 IV given on day 2 of every 21-day cycle for 6 cycles in untreated patients with primary central nervous system lymphoma</description>
    <arm_group_label>C-R-MTX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ECOG Performance Status of 0, 1, or 2&#xD;
&#xD;
          2. Previously untreated patients with primary central nervous system lymphoma with&#xD;
             pathologically confirm&#xD;
&#xD;
          3. At least one bi-dimensionally measurable lesion, defined as &gt;1.0 cm in its longest&#xD;
             dimension as measured by MRI&#xD;
&#xD;
          4. Signed written Informed Consent Form&#xD;
&#xD;
          5. hematologic function,defined as follows:&#xD;
&#xD;
               -  Hemoglobin ³ 9.0 g/dL without packed RBC transfusion during 14 days before first&#xD;
                  treatment&#xD;
&#xD;
               -  ANC ³ 1,000/µL&#xD;
&#xD;
               -  Platelet count ³ 80,000/µL&#xD;
&#xD;
          6. Adequate liver and kidney function function,defined as follows:&#xD;
&#xD;
        Serum AST and ALT≤ 2.5 *ULN ，Total bilirubin ≤ 1.5 * ULN Serum creatinine clearance ≥ 50&#xD;
        mL/min (using Cockcroft-Gault formula)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of extracranial involvement (such as testis and breast) and secondary CNS&#xD;
             involvement&#xD;
&#xD;
          2. Evidence of pleural fluid, ascites and pericardial effusion&#xD;
&#xD;
          3. History or presence of prolonged QTc interval in ECG, QTc interval&gt;470ms in female and&#xD;
             &gt;450ms in male&#xD;
&#xD;
          4. History of other malignancy in 5 years&#xD;
&#xD;
          5. Positive test results for hepatitis C, HIV and RPR.&#xD;
&#xD;
          6. Positive test results for chronic hepatitis B infection (defined as positive hepatitis&#xD;
             B surface antigen [HBsAg] serology) Patients with occult or prior hepatitis B&#xD;
             infection (defined as positive total hepatitis B core antibody and negative HBsAg) may&#xD;
             be included if hepatitis B virus (HBV) DNA is less than 10E4 at the time of screening.&#xD;
&#xD;
          7. Pregnancy or lactation or intending to become pregnant during study&#xD;
&#xD;
          8. Prior organ transplantation&#xD;
&#xD;
          9. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection at&#xD;
             study enrollment or significant infections within 2 weeks before the start of Cycle 1.&#xD;
&#xD;
         10. Evidence of significant, uncontrolled, epilepsy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fangfang Lv</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fangfang Lv</last_name>
    <phone>+86-18018312613</phone>
    <email>lvff80@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jia Jin</last_name>
    <phone>+86-18017317721</phone>
    <email>jinjia195@126.com</email>
  </overall_contact_backup>
  <results_reference>
    <citation>Gerstner ER, Batchelor TT. Primary central nervous system lymphoma. Arch Neurol. 2010 Mar;67(3):291-7. doi: 10.1001/archneurol.2010.3. Review.</citation>
    <PMID>20212226</PMID>
  </results_reference>
  <results_reference>
    <citation>Batchelor TT. Primary central nervous system lymphoma: A curable disease. Hematol Oncol. 2019 Jun;37 Suppl 1:15-18. doi: 10.1002/hon.2598. Review.</citation>
    <PMID>31187523</PMID>
  </results_reference>
  <results_reference>
    <citation>Batchelor T, Carson K, O'Neill A, Grossman SA, Alavi J, New P, Hochberg F, Priet R. Treatment of primary CNS lymphoma with methotrexate and deferred radiotherapy: a report of NABTT 96-07. J Clin Oncol. 2003 Mar 15;21(6):1044-9.</citation>
    <PMID>12637469</PMID>
  </results_reference>
  <results_reference>
    <citation>Chamberlain MC, Johnston SK. High-dose methotrexate and rituximab with deferred radiotherapy for newly diagnosed primary B-cell CNS lymphoma. Neuro Oncol. 2010 Jul;12(7):736-44. doi: 10.1093/neuonc/noq011. Epub 2010 Feb 8.</citation>
    <PMID>20511181</PMID>
  </results_reference>
  <results_reference>
    <citation>DeAngelis LM, Seiferheld W, Schold SC, Fisher B, Schultz CJ; Radiation Therapy Oncology Group Study 93-10. Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol. 2002 Dec 15;20(24):4643-8.</citation>
    <PMID>12488408</PMID>
  </results_reference>
  <results_reference>
    <citation>Gavrilovic IT, Hormigo A, Yahalom J, DeAngelis LM, Abrey LE. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2006 Oct 1;24(28):4570-4.</citation>
    <PMID>17008697</PMID>
  </results_reference>
  <results_reference>
    <citation>Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D, LaRocca R, Grant B, DeAngelis LM, Abrey LE. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma. J Clin Oncol. 2007 Oct 20;25(30):4730-5. Erratum in: J Clin Oncol. 2008 Jan 10;26(2):340.</citation>
    <PMID>17947720</PMID>
  </results_reference>
  <results_reference>
    <citation>Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15;18(4):1146-55. doi: 10.1158/1078-0432.CCR-11-0625. Epub 2012 Jan 6.</citation>
    <PMID>22228634</PMID>
  </results_reference>
  <results_reference>
    <citation>Gregory G, Arumugaswamy A, Leung T, Chan KL, Abikhair M, Tam C, Bajel A, Cher L, Grigg A, Ritchie D, Opat S. Rituximab is associated with improved survival for aggressive B cell CNS lymphoma. Neuro Oncol. 2013 Aug;15(8):1068-73. doi: 10.1093/neuonc/not032. Epub 2013 Mar 15.</citation>
    <PMID>23502429</PMID>
  </results_reference>
  <results_reference>
    <citation>Holdhoff M, Ambady P, Abdelaziz A, Sarai G, Bonekamp D, Blakeley J, Grossman SA, Ye X. High-dose methotrexate with or without rituximab in newly diagnosed primary CNS lymphoma. Neurology. 2014 Jul 15;83(3):235-9. doi: 10.1212/WNL.0000000000000593. Epub 2014 Jun 13.</citation>
    <PMID>24928128</PMID>
  </results_reference>
  <results_reference>
    <citation>Ly KI, Crew LL, Graham CA, Mrugala MM. Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: A single-institution experience. Oncol Lett. 2016 May;11(5):3471-3476. Epub 2016 Mar 30.</citation>
    <PMID>27123138</PMID>
  </results_reference>
  <results_reference>
    <citation>Omuro A, Correa DD, DeAngelis LM, Moskowitz CH, Matasar MJ, Kaley TJ, Gavrilovic IT, Nolan C, Pentsova E, Grommes CC, Panageas KS, Baser RE, Faivre G, Abrey LE, Sauter CS. R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma. Blood. 2015 Feb 26;125(9):1403-10. doi: 10.1182/blood-2014-10-604561. Epub 2015 Jan 7.</citation>
    <PMID>25568347</PMID>
  </results_reference>
  <results_reference>
    <citation>Glass J, Won M, Schultz CJ, Brat D, Bartlett NL, Suh JH, Werner-Wasik M, Fisher BJ, Liepman MK, Augspurger M, Bokstein F, Bovi JA, Solhjem MC, Mehta MP. Phase I and II Study of Induction Chemotherapy With Methotrexate, Rituximab, and Temozolomide, Followed By Whole-Brain Radiotherapy and Postirradiation Temozolomide for Primary CNS Lymphoma: NRG Oncology RTOG 0227. J Clin Oncol. 2016 May 10;34(14):1620-5. doi: 10.1200/JCO.2015.64.8634. Epub 2016 Mar 28.</citation>
    <PMID>27022122</PMID>
  </results_reference>
  <results_reference>
    <citation>Song Y, Wen Y, Xue W, Zhang Y, Zhang M. Effect of rituximab on primary central nervous system lymphoma: a meta-analysis. Int J Hematol. 2017 Nov;106(5):612-621. doi: 10.1007/s12185-017-2316-z. Epub 2017 Sep 12. Review.</citation>
    <PMID>28900847</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferreri AJ, Reni M, Foppoli M, Martelli M, Pangalis GA, Frezzato M, Cabras MG, Fabbri A, Corazzelli G, Ilariucci F, Rossi G, Soffietti R, Stelitano C, Vallisa D, Zaja F, Zoppegno L, Aondio GM, Avvisati G, Balzarotti M, Brandes AA, Fajardo J, Gomez H, Guarini A, Pinotti G, Rigacci L, Uhlmann C, Picozzi P, Vezzulli P, Ponzoni M, Zucca E, Caligaris-Cappio F, Cavalli F; International Extranodal Lymphoma Study Group (IELSG). High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet. 2009 Oct 31;374(9700):1512-20. doi: 10.1016/S0140-6736(09)61416-1. Epub 2009 Sep 18.</citation>
    <PMID>19767089</PMID>
  </results_reference>
  <results_reference>
    <citation>Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P, Paleologos N, Correa DD, Anderson ND, Caron D, Zelenetz A, Nimer SD, DeAngelis LM. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol. 2003 Nov 15;21(22):4151-6.</citation>
    <PMID>14615443</PMID>
  </results_reference>
  <results_reference>
    <citation>Colombat P, Lemevel A, Bertrand P, Delwail V, Rachieru P, Brion A, Berthou C, Bay JO, Delepine R, Desablens B, Camilleri-Broët S, Linassier C, Lamy T. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant. 2006 Sep;38(6):417-20.</citation>
    <PMID>16951691</PMID>
  </results_reference>
  <results_reference>
    <citation>Illerhaus G, Müller F, Feuerhake F, Schäfer AO, Ostertag C, Finke J. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica. 2008 Jan;93(1):147-8. doi: 10.3324/haematol.11771.</citation>
    <PMID>18166803</PMID>
  </results_reference>
  <results_reference>
    <citation>Cote GM, Hochberg EP, Muzikansky A, Hochberg FH, Drappatz J, McAfee SL, Batchelor TT, LaCasce AS, Fisher DC, Abramson JS, Armand P, Chen YB. Autologous stem cell transplantation with thiotepa, busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma. Biol Blood Marrow Transplant. 2012 Jan;18(1):76-83. doi: 10.1016/j.bbmt.2011.07.006. Epub 2011 Jul 13.</citation>
    <PMID>21749848</PMID>
  </results_reference>
  <results_reference>
    <citation>Ferreri AJM, Cwynarski K, Pulczynski E, Fox CP, Schorb E, La Rosée P, Binder M, Fabbri A, Torri V, Minacapelli E, Falautano M, Ilariucci F, Ambrosetti A, Roth A, Hemmaway C, Johnson P, Linton KM, Pukrop T, Sønderskov Gørløv J, Balzarotti M, Hess G, Keller U, Stilgenbauer S, Panse J, Tucci A, Orsucci L, Pisani F, Levis A, Krause SW, Schmoll HJ, Hertenstein B, Rummel M, Smith J, Pfreundschuh M, Cabras G, Angrilli F, Ponzoni M, Deckert M, Politi LS, Finke J, Reni M, Cavalli F, Zucca E, Illerhaus G; International Extranodal Lymphoma Study Group (IELSG). Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017 Nov;4(11):e510-e523. doi: 10.1016/S2352-3026(17)30174-6. Epub 2017 Oct 17.</citation>
    <PMID>29054815</PMID>
  </results_reference>
  <results_reference>
    <citation>Thiel E, Korfel A, Martus P, Kanz L, Griesinger F, Rauch M, Röth A, Hertenstein B, von Toll T, Hundsberger T, Mergenthaler HG, Leithäuser M, Birnbaum T, Fischer L, Jahnke K, Herrlinger U, Plasswilm L, Nägele T, Pietsch T, Bamberg M, Weller M. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010 Nov;11(11):1036-47. doi: 10.1016/S1470-2045(10)70229-1. Epub 2010 Oct 20.</citation>
    <PMID>20970380</PMID>
  </results_reference>
  <results_reference>
    <citation>Mohile NA, Deangelis LM, Abrey LE. The utility of body FDG PET in staging primary central nervous system lymphoma. Neuro Oncol. 2008 Apr;10(2):223-8. doi: 10.1215/15228517-2007-061. Epub 2008 Feb 20.</citation>
    <PMID>18287338</PMID>
  </results_reference>
  <results_reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang H, Li C, Chen Z, Mou H, Gu L. Determination of chidamide in rat plasma and cerebrospinal fluid. Regul Toxicol Pharmacol. 2018 Oct;98:24-30. doi: 10.1016/j.yrtph.2018.07.001. Epub 2018 Jul 6.</citation>
    <PMID>30008379</PMID>
  </results_reference>
  <results_reference>
    <citation>Abrey LE, Batchelor TT, Ferreri AJ, Gospodarowicz M, Pulczynski EJ, Zucca E, Smith JR, Korfel A, Soussain C, DeAngelis LM, Neuwelt EA, O'Neill BP, Thiel E, Shenkier T, Graus F, van den Bent M, Seymour JF, Poortmans P, Armitage JO, Cavalli F; International Primary CNS Lymphoma Collaborative Group. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005 Aug 1;23(22):5034-43. Epub 2005 Jun 13.</citation>
    <PMID>15955902</PMID>
  </results_reference>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 11, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2020</study_first_posted>
  <last_update_submitted>August 14, 2020</last_update_submitted>
  <last_update_submitted_qc>August 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Fangfang Lv, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

